The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection
AbstractThe pharmaceutical industry has an outstanding record of innovative performance over the past 50 years. The R&D process has become more knowledge-based and a market for innovation has emerged between research start-ups, development-stage firms, and the larger, multinational companies. At the same time, R&D costs have increased several fold over time and generic products now dominate many traditional therapeutic areas. The current challenge for the industry is to discover new therapies for chronic diseases with high unmet needs like Alzheimer's disease and various auto-immune diseases and cancers that afflict an increasingly aging population. Recent advances in molecular biology and related fields provide a scientific foundation to undertake these R&D efforts, although the time path and outcomes remain subject to many risks and uncertainties.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoArticle provided by Taylor and Francis Journals in its journal International Journal of the Economics of Business.
Volume (Year): 18 (2011)
Issue (Month): 2 ()
Contact details of provider:
Web page: http://taylorandfrancis.metapress.com/link.asp?target=journal&id=101205
You can help add them by filling out this form.
reading list or among the top items on IDEAS.Access and download statisticsgeneral information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Michael McNulty).
If references are entirely missing, you can add them using this form.